BioPlatforms(5)
-
A Novel Platform for Rapid Generation of Covalent Biotherapeutics (No. T4-2282)
Covalent drugs have emerged as a groundbreaking modality for improving the affinity, potency, and duration of action of molecularly targeted inhibitors. Prof. ... Read more18694 -
Adapters for Targeted Viral Vector-Based Therapies (No. T4-2229)
A major challenge in developing viral-based therapies, such as gene therapies, CAR-T cell immunotherapy, and oncolytic virotherapy, is that the most efficient vectors and viruses are not specific, preventing their direct administration to the patient. Prof. ... Read more18691 -
High Throughput Screening Platform For Inhibitors of Viral Membrane Fusion (No. T4-2213)
Enveloped viruses pose significant health risks and lack effective treatments. Inhibiting viral membrane fusion, a crucial step in infection, holds promise for antiviral drug development. Dr. ... Read more18679 -
Safer CAR-T Cell Platform (No. T4-2033)
Chimeric Antigen Receptor (CAR)-T Cell Therapy is a personalized treatment for cancer in which the patient's T cells are genetically engineered to express a synthetic receptor that binds a tumor antigen. ... Read more6124 -
A Method to Identify Actively Degraded Proteins (No. T4-1832)
This technology provides a method to identify the full landscape of proteins that are actively being degraded by the proteasome, offering a way to identify novel targets in various biological conditions and contexts. ... Read more6030
![Subscribe to BioPlatforms](https://www.yedarnd.com/misc/feed.png)